Medannex awarded ‘Transforming Cancer Therapeutics’ grant to accelerate new treatment for bone cancer in children

MDX-124 is the first clinic-ready agent to target annexin-A1, a protein known to drive numerous cancers and other diseases. In preclinical tests, MDX-124 has been shown to stop the growth and spread of certain cancers, as well as harnessing the immune system to attack tumours. MDX-124 is currently being evaluated in a first-in-human Phase 1b oncology study in adults (‘ATTAINMENT’). 

Recent data mining of a paediatric genomics database and staining of tumour tissue revealed that annexin-A1 is highly expressed in osteosarcoma, making MDX-124 a strong candidate to treat this disease. 

Medannex today announced an Innovate UK grant to fund a £313,000 project developing a new treatment for paediatric osteosarcoma. The ‘Transforming Cancer Therapeutics’ award will allow the Scottish biopharmaceutical company to prepare its first-in-class therapy (MDX-124) for a clinical study in this rare childhood cancer.